Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-06-13Clinical Trial Update: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating atezolizumab with obinutuzumab-based regimens in follicular lymphoma and diffuse large B-cell lymphoma has been c…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]
Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-05-30Clinical Trial Update: Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]
Phase 3 clinical trial update for TQB2303 in CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) is provided, with status not specified.
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial comparing denintuzumab mafodotin plus RICE versus RICE alone in diffuse large B-cell lymphoma; the study is terminated with re…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial investigating intensive consolidation and stem cell mobilization followed by autologous stem cell transplantation in high-risk…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL [Phase 2]
Phase 2 trial evaluating ibrutinib with bendamustine and rituximab for relapsed/refractory aggressive B-cell lymphomas, with several DLBCL-r…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating tandem CAR T cells targeting CD19 and CD22 for relapsed or chemotherapy-refractory B-cell malignancies.
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating CAR T cell receptor immunotherapy for B-cell lymphomas completed with posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-03-19Clinical Trial Update: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma [Phase 3]
Phase 3 trial evaluating ibrutinib in combination with R-CHOP in newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating memory-enriched CAR-T cell therapy for various recurrent B cell lymphomas, including diffuse large B c…
-
CLINICAL_TRIALS trial_result · 2019-02-22Clinical Trial Update: EBV-associated Diffuse Large B Cell Lymphoma
The trial update notes the completed study on EBV-associated diffuse large B-cell lymphoma, focusing on clinical, pathological, and molecula…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL [Phase 1]
Phase 1 clinical trial evaluating a five-drug combination (lenalidomide, rituximab, gemcitabine, oxaliplatin, dexamethasone) for relapsed or…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. [Phase 2]
This entry reports a Phase 2 trial evaluating the Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) regimen in previously untreated elderly patien…
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in relapsed or refractory diffuse large …
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas [Phase 1]
Phase 1 study of alisertib plus romidepsin in relapsed or refractory B-cell and T-cell lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) [Phase 2]
Phase 2 study evaluating novel approaches to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation, with res…
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma [NA]
This update notes completion of a trial evaluating FDG-PET-stratified R-DICEP and R-Beam/ASCT approaches for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-01-17Clinical Trial Update: A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects [Phase 1]
A Phase 1 trial evaluating the safety and preliminary efficacy of C-CAR011 in patients with refractory diffuse large B-cell lymphoma has com…
-
CLINICAL_TRIALS trial_result · 2019-01-08Clinical Trial Update: Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma [Phase 2]
Phase 2 trial assessing denintuzumab mafodotin (SGN-CD19A) with RCHOP/RCHP vs RCHOP alone in diffuse large B-cell lymphoma and follicular ly…
-
CLINICAL_TRIALS trial_result · 2019-01-04Clinical Trial Update: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
Phase 2 results from a study using donor umbilical cord blood stem cell transplants in patients with hematologic malignancies have been post…
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma [Phase 3]
Phase 3 trial comparing R-GemOx to R-miniCHOP as first-line therapy for elderly patients with diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-12-20Clinical Trial Update: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL [Phase 1, Phase 2]
Phase 1/2 study evaluating venetoclax with chemotherapy in B-cell non-Hodgkin lymphoma and diffuse large B-cell lymphoma has completed with …
-
CLINICAL_TRIALS trial_result · 2018-10-25Clinical Trial Update: Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial investigating azacitidine and rituximab-GDP immunochemotherapy for relapsed/refractory diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab and bendamustine with or without brentuximab vedotin in CD30-positive diffuse large B-cell lymphoma and r…
-
CLINICAL_TRIALS trial_result · 2018-10-01Clinical Trial Update: A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) [Phase 1]
Phase 1 dose-finding study of the bromodomain inhibitor birabresib (OTX015/MK-8628) in hematologic malignancies has completed with results p…